Skip to content

Low-dose cyclosporin A in severe psoriasis: a double-blind study

Br J Dermatol. 1988 Feb;118(2):183-90. Low-dose cyclosporin A in severe psoriasis. A double-blind study. Van Joost T(1), Bos JD, Heule F, Meinardi MM. In the first, double-blind part of the study, 133 patients with moderate to severe psoriasis were randomized to receive a daily dose of 1.25 or 2.5 mg cyclosporin A/kg or placebo for a period of 10 weeks (period I). Meinardi MMHM. Low-dose cyclosporin A in severe psoriasis. A double-blind study on ResearchGate, the professional network for scientists.

Low-dose cyclosporin A in severe psoriasis: a double-blind study 2A randomized parallel-group study in adults with severe psoriasis (Table 1) compared daily CsA doses of 100 300 mg, given in a body-weight-independent (BWI) manner, or 1. Long-term low-dosecyclosporine therapy for severe psoriasis: effects on renal function andstructure. Methotrexate vs cyclosporin in psoriasis:effectiveness, quality of life and safety. Y. Etretinate in severe psoriasis: results of double-blind study andmaintenance therapy in pustular psoriasis. JAMA 1986;256: 3110-3116. Van Joost T, Bos JD, Heule F, et al: Low-dose study cyclosporin A in severe psoriasis. A double-blind study.

Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial1,2,3. The study was investigator blinded, ie, the dermatologist who performed the PASI scoring was unaware of the randomization assignment. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis OLP302 Study Group. The outcome of placebo treatment was poor in most studies. Low-dose cyclosporin A in severe psoriasis. A double blind study.

Cyclosporine Regimens In Plaque Psoriasis: An Overview With Special Emphasis On Dose, Duration, And Old And New Treatment Approaches

Efficacy of ustekinumab in palmoplantar psoriasis 3JG, Voorhees, JJ: Cyclosporin A improves psoriasis in a double blind study. Bos, JD, Heule, F, Meinardi, MM: Low-dose cyclosporine A in severe psoriasis. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. Et al, Double-blind placebo-controlled study of long-term low-dose cyclosporine in the treatment of palmoplantar pustulosis. R. et al, Cyclosporine as maintenance therapy in patients with severe psoriasis. This study will evaluate whether lower doses of cyclosporine can cause fewer side effects and still produce the same beneficial results that are seen with a standard cyclosporine dose regimen when treating individuals with moderate to severe psoriasis. Purpose This study will evaluate whether lower doses of cyclosporine can cause fewer side effects and still produce the same beneficial results that are seen with a standard cyclosporine dose regimen when treating individuals with moderate to severe psoriasis.

Weight Loss Improves The Response Of Obese Patients With Moderate-to-severe Chronic Plaque Psoriasis To Low-dose Cyclosporine Therapy: A Randomized, Controlled, Investigator-blinded Clinical Trial